How should source and synthetic health data be protected, managed and reused? SYNTHEMA deliverable D5.4 updates our Data Management Plan, covering FAIR principles, security, privacy risks, ethics, interoperability and sustainability. 👉 synthema.eu/public-deliv...

Cancer research often works with limited data, while many synthetic data models need thousands of samples. This paper explores how transfer learning and meta-learning can improve synthetic tabular data generation in low-data medical scenarios. Access it via SYNTHEMA: synthema.eu/publications/

🔬How do we safely validate synthetic data for clinical research? Our new deliverable (D4.1) outlines a rigorous three-tiered framework—testing VAEs, GANs, and diffusion models on leukaemia and sickle cell disease datasets. 👉Access the full report: synthema.eu/public-deliv...

In the latest issue of our newsletter, we have compiled the outcomes and resources of our complete training programme on synthetic data in haematology into one accessible guide. Access the full material and webinar recordings here: 👉 zenodo.org/records/2139...

Cybersecurity risk assessment gets harder when assets, threats and consequences are deeply connected. This paper presents an automated, knowledge-based approach for cyber-physical systems, implemented through the open-source Spyderisk project. 👉 synthema.eu/publications/

Healthcare data cannot always be centralised, but treatment effects still need to be estimated. A paper by Alejandro Almodovar, Juan Parras and Santiago Zazo explores federated learning for causal inference using deep generative disentangled models. Access the paper: synthema.eu/publications/

What does it really mean for synthetic data to be private? This systematic review digs into 105 studies to map how privacy in SDG is defined, evaluated & applied, spotlighting differential privacy, GANs & healthcare use. 👉Available at: synthema.eu/publications/

#SYNTHEMA is building the foundations for a future where synthetic, privacy-preserving data supports progress in rare diseases. Beyond its two use cases, its flexible design can benefit other rare and underrepresented conditions. More 👉 synthema.eu

In 1 hour, we are starting the final session of the SYNTHEMA and @erneurobloodnet.bsky.social training programme. Today’s session will explore how synthetic data can support research in Sickle Cell Disease and Acute Myeloid Leukaemia. 👉 Register, it’s free: synthema.eu/training/

New publication from the SYNTHEMA project 👇 Researchers developed a two-stage framework to assess privacy risks in Federated Learning and generative AI, showing when client updates remain detectable and can be linked to private data. Access the paper: synthema.eu/publications/

In 1 hour, we are starting the third SYNTHEMA and @erneurobloodnet.bsky.social session. Today’s discussion will focus on interoperability, synthetic data and how health data can be standardised, shared and reused across systems. 👉 Register, it’s free: synthema.eu/training/

Interested in synthetic data and AI-powered breakthroughs in hematology? Visit SYNTHEMA’s publications section to explore the latest advancements by our team in data privacy, federated learning, AI for rare blood diseases, and more. 👉Start reading: synthema.eu/publications #SYNTHEMA #SyntheticData

Starting in 1 hour! Today’s SYNTHEMA and @erneurobloodnet.bsky.social session will focus on the regulatory and ethical context for AI in healthcare, including MDR, the EU AI Act and privacy-preserving federated learning. 👉 Register, it’s free: synthema.eu/training/

The SYNTHEMA M42 meeting in Rome wrapped up after two productive days of collaboration. Partners aligned on the final phase of the project, including the white paper, webinars, and sustainability of results. Thanks to Datawizard for hosting us 🫶 synthema.eu

Saluti da Roma! 🇮🇹 The SYNTHEMA consortium is in Rome this week for the project’s M42 meeting, hosted by Datawizard. Over the next two days, partners will coordinate the final phase of the project as SYNTHEMA enters its last six months. More about our work: synthema.eu

Today is Europe Day 🇪🇺 #SYNTHEMA brings together partners across Europe to advance AI-powered anonymisation and synthetic data generation for research on rare haematological diseases. 👉https://synthema.eu/ #EuropeDay #HealthInnovation

The #SYNTHEMA and @erneurobloodnet.bsky.social training programme starts this week. The first session is taking place this Friday, 8 May at 12:30 CEST, focusing on infrastructure for synthetic data generation. If you have not registered yet, now is the time. 👉 synthema.eu/training/

Ever heard of synthetic data? It helps protect privacy, improve healthcare innovation, and still relies on real patient data. Your voice matters. Take part in the European survey on synthetic data in healthcare (12–15 minutes), find out more: bit.ly/4c7if0o #SYNTHIA

SYNTHEMA is part of the #HealthData4EU cluster, working to make health data more accessible, secure and interoperable. Its work focuses on synthetic data, federated learning and privacy-preserving technologies. Interested in synthetic data? 👉 Join the webinar series: synthema.eu/training/

Artificial intelligence is already being applied in rare haematological diseases. The #SYNTHEMA and @erneurobloodnet.bsky.social training programme, led by experts from the field, covers synthetic data, federated learning, regulation and clinical use cases. Register: synthema.eu/training/

Sickle Cell Disease is a rare, life-threatening blood disorder with limited treatment options. In SYNTHEMA’s Use Case 2, AI generates synthetic data from 1,000+ patients to study genetic factors & predict brain vascular events, while protecting privacy. 👉 synthema.eu/use-cases/

How will synthetic data be applied in real research? This final session will present use cases in Sickle Cell Disease and Acute Myeloid Leukaemia as part of the joint #SYNTHEMA and @erneurobloodnet.bsky.social training programme. 👉 Register: synthema.eu/training/

#AML is the most common acute leukemia in adults – fast-progressing but treatable. In SYNTHEMA’s Use Case 1, AI creates synthetic data from 2,500+ AML patients to predict survival & treatment responses, while protecting privacy. 👉Learn more about our approach: synthema.eu

How can synthetic health data be standardised, shared and reused across systems? Don’t miss this session on interoperability and synthetic data as part of the joint #SYNTHEMA and @erneurobloodnet.bsky.social training programme. 👉 Register: synthema.eu/training/

#SYNTHEMA enables research on diseases like leukaemia and sickle cell without exposing patient data, using AI-generated synthetic datasets. Our models create realistic clinical, genetic, and imaging data, supporting safe and privacy-first research. 👉 synthema.eu #AIInMedicine

If you're interested in regulation and ethics in AI for healthcare, don’t miss this session on MDR, the EU AI Act and privacy-preserving federated learning as part of the joint #SYNTHEMA and @erneurobloodnet.bsky.social training programme. 👉 Register: synthema.eu/training/

Missed it? The BDVA Healthcare Task Force white paper on synthetic data features #SYNTHEMA, led by Netcompany, alongside AISym4MED and SECURED. It shows how synthetic data can expand access, improve AI and enable more inclusive research. Access the paper: synthema.eu/publications/

Registration is open for the SYNTHEMA & @erneurobloodnet.bsky.social in haematology webinar series. Join all 4 sessions in May 2026 or register for individual webinars. Synthetic data, federated learning, regulation and clinical use cases in AML and SCD. Register: synthema.eu/training/

Good data is not just collected, it is built with care. In #SYNTHEMA, clinical teams across Europe are creating high-quality, privacy-compliant datasets to power synthetic data and AI research in rare blood disorders. 👉Read more: synthema.eu/2025/09/23/d...

Netcompany has published the SYNTHEMA SMPC federated learning app on the Flower Hub. It enables secure aggregation of model updates while keeping data private. 👉 Explore the app: flower.ai/apps/synthem...